Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Acurx Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001736243.
Disclosed value leader
David P. Luci
Comparable rows
22/30
Latest evidence
20 Apr 2026
- Public ticker
- ACXP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
22 of 30
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
20 Apr 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001736243
- Issuer location
- Staten Island, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Acurx Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
David P. Luci
Comparable rows
22/30
Latest evidence
20 Apr 2026
13D/G
13F
3/4/5
Lead comparable stake: 5%
8 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 30 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
22 of 30 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
JANE STREET GROUP, LLC
0.42%
VANGUARD CAPITAL MANAGEMENT LLC
0.24%
GEODE CAPITAL MANAGEMENT, LLC
0.19%
Cambridge Investment Research Adv...
0.16%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 30 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$62,591
83,233 shares
|
-$2,131,726 | 30 Sep 2025 |
| JANE STREET GROUP, LLC |
13F
Company
|
0.42%
|
$202,722
54,642 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.24%
|
$115,377
31,099 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.19%
|
$92,080
24,819 shares
|
— | 31 Mar 2026 |
| Cambridge Investment Research Advisors, Inc. |
13F
Company
|
0.16%
|
$74,000
20,000 shares
|
— | 31 Mar 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.13%
|
$60,121
16,205 shares
|
— | 31 Mar 2026 |
| Prospect Financial Services LLC |
13F
Company
|
0.11%
|
$51,144
13,785 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
Company
|
0.05%
|
$24,115
6,500 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 12 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-8 of 8 reporting-owner rows connected to Acurx Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
8
Largest Forms 3/4/5 holder
David P. Luci
Net 12M change
$0
Latest report
20 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David P. Luci | President and CEO, Director | $1,164,754 | Mixed | 20 Apr 2026 | ||
| DELUCCIA ROBERT J | Director | $1,029,254 | Mixed | 20 Apr 2026 | ||
| Carl V Sailer | Director | $144,316 | Mixed | 20 Apr 2026 | ||
| Joseph C. Scodari | Director | $28,124 | Filing P/S | 20 Apr 2026 | ||
| Jack H. Dean | Director | $27,960 | Mixed | 20 Apr 2026 | ||
| James J. Donohue | Director | $22,687 | Filing P/S | 20 Apr 2026 | ||
| Robert G. Shawah | Chief Financial Officer | Mixed | 20 Apr 2026 | |||
| Thomas L. Harrison | Director | Mixed | 20 Apr 2026 |
Recent insider transactions for Acurx Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Carl V Sailer | ACXP | Stock Option | Award | 2,150 | 2,150 | 20 Apr 2026 | Direct | |||
| Jack H. Dean | ACXP | Stock Option | Award | 2,150 | 2,150 | 20 Apr 2026 | Direct | |||
| James J. Donohue | ACXP | Stock Option | Award | 2,150 | 2,150 | 20 Apr 2026 | Direct | |||
| Thomas L. Harrison | ACXP | Stock Option | Award | 2,150 | 2,150 | 20 Apr 2026 | Direct | |||
| Joseph C. Scodari | ACXP | Stock Option | Award | 2,150 | 2,150 | 20 Apr 2026 | Direct | |||
| Deluccia Robert J | ACXP | Stock Option | Award | 37,100 | 37,100 | 20 Apr 2026 | Direct | |||
| David P. Luci | ACXP | Stock Option | Award | 37,100 | 37,100 | 20 Apr 2026 | Direct | |||
| Robert G. Shawah | ACXP | Stock Option | Award | 25,900 | 25,900 | 20 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.